These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 21108947)

  • 1. Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart.
    McKinsey TA
    J Mol Cell Cardiol; 2011 Oct; 51(4):491-6. PubMed ID: 21108947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The biology and therapeutic implications of HDACs in the heart.
    McKinsey TA
    Handb Exp Pharmacol; 2011; 206():57-78. PubMed ID: 21879446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potential for HDAC inhibitors in the heart.
    McKinsey TA
    Annu Rev Pharmacol Toxicol; 2012; 52():303-19. PubMed ID: 21942627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting histone deacetylases for heart failure.
    Bush EW; McKinsey TA
    Expert Opin Ther Targets; 2009 Jul; 13(7):767-84. PubMed ID: 19466913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isoform-specific histone deacetylase inhibitors: the next step?
    Balasubramanian S; Verner E; Buggy JJ
    Cancer Lett; 2009 Aug; 280(2):211-21. PubMed ID: 19289255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding.
    Kee HJ; Sohn IS; Nam KI; Park JE; Qian YR; Yin Z; Ahn Y; Jeong MH; Bang YJ; Kim N; Kim JK; Kim KK; Epstein JA; Kook H
    Circulation; 2006 Jan; 113(1):51-9. PubMed ID: 16380549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.
    Weichert W; Röske A; Niesporek S; Noske A; Buckendahl AC; Dietel M; Gekeler V; Boehm M; Beckers T; Denkert C
    Clin Cancer Res; 2008 Mar; 14(6):1669-77. PubMed ID: 18347167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inside HDAC with HDAC inhibitors.
    Bertrand P
    Eur J Med Chem; 2010 Jun; 45(6):2095-116. PubMed ID: 20223566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
    Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
    Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors.
    Bush EW; McKinsey TA
    Circ Res; 2010 Feb; 106(2):272-84. PubMed ID: 20133912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure.
    Gallo P; Latronico MV; Gallo P; Grimaldi S; Borgia F; Todaro M; Jones P; Gallinari P; De Francesco R; Ciliberto G; Steinkühler C; Esposito G; Condorelli G
    Cardiovasc Res; 2008 Dec; 80(3):416-24. PubMed ID: 18697792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension.
    Lemon DD; Horn TR; Cavasin MA; Jeong MY; Haubold KW; Long CS; Irwin DC; McCune SA; Chung E; Leinwand LA; McKinsey TA
    J Mol Cell Cardiol; 2011 Jul; 51(1):41-50. PubMed ID: 21539845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-sirtuin histone deacetylases in the control of cardiac aging.
    Ferguson BS; McKinsey TA
    J Mol Cell Cardiol; 2015 Jun; 83():14-20. PubMed ID: 25791169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting inflammation in heart failure with histone deacetylase inhibitors.
    McKinsey TA
    Mol Med; 2011; 17(5-6):434-41. PubMed ID: 21267510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitors in cancer therapy.
    Lane AA; Chabner BA
    J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for HDAC inhibitor therapy in autoimmunity and transplantation.
    Hancock WW
    Handb Exp Pharmacol; 2011; 206():103-23. PubMed ID: 21879448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative analysis of histone deacetylase-1 selective histone modifications by differential mass spectrometry.
    Lee AY; Paweletz CP; Pollock RM; Settlage RE; Cruz JC; Secrist JP; Miller TA; Stanton MG; Kral AM; Ozerova ND; Meng F; Yates NA; Richon V; Hendrickson RC
    J Proteome Res; 2008 Dec; 7(12):5177-86. PubMed ID: 19367703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylases as therapeutic targets--from cancer to cardiac disease.
    Abend A; Kehat I
    Pharmacol Ther; 2015 Mar; 147():55-62. PubMed ID: 25444758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases.
    Wang DF; Helquist P; Wiech NL; Wiest O
    J Med Chem; 2005 Nov; 48(22):6936-47. PubMed ID: 16250652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors.
    Smil DV; Manku S; Chantigny YA; Leit S; Wahhab A; Yan TP; Fournel M; Maroun C; Li Z; Lemieux AM; Nicolescu A; Rahil J; Lefebvre S; Panetta A; Besterman JM; Déziel R
    Bioorg Med Chem Lett; 2009 Feb; 19(3):688-92. PubMed ID: 19111466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.